These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 32976979)
1. Hepatocyte growth factor/MET and CD44 in colorectal cancer: partners in tumorigenesis and therapy resistance. Joosten SPJ; Spaargaren M; Clevers H; Pals ST Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188437. PubMed ID: 32976979 [TBL] [Abstract][Full Text] [Related]
2. MET Signaling Mediates Intestinal Crypt-Villus Development, Regeneration, and Adenoma Formation and Is Promoted by Stem Cell CD44 Isoforms. Joosten SPJ; Zeilstra J; van Andel H; Mijnals RC; Zaunbrecher J; Duivenvoorden AAM; van de Wetering M; Clevers H; Spaargaren M; Pals ST Gastroenterology; 2017 Oct; 153(4):1040-1053.e4. PubMed ID: 28716720 [TBL] [Abstract][Full Text] [Related]
3. Expression of c-Met and heparan-sulfate proteoglycan forms of CD44 in colorectal cancer. Wielenga VJ; van der Voort R; Taher TE; Smit L; Beuling EA; van Krimpen C; Spaargaren M; Pals ST Am J Pathol; 2000 Nov; 157(5):1563-73. PubMed ID: 11073815 [TBL] [Abstract][Full Text] [Related]
4. Stromal hyaluronan interaction with epithelial CD44 variants promotes prostate cancer invasiveness by augmenting expression and function of hepatocyte growth factor and androgen receptor. Ghatak S; Hascall VC; Markwald RR; Misra S J Biol Chem; 2010 Jun; 285(26):19821-32. PubMed ID: 20200161 [TBL] [Abstract][Full Text] [Related]
5. Activation of c-Met and upregulation of CD44 expression are associated with the metastatic phenotype in the colorectal cancer liver metastasis model. Elliott VA; Rychahou P; Zaytseva YY; Evers BM PLoS One; 2014; 9(5):e97432. PubMed ID: 24823486 [TBL] [Abstract][Full Text] [Related]
6. Dissecting Oncogenic RTK Pathways in Colorectal Cancer Initiation and Progression. McManus S; Chababi W; Arsenault D; Dubois CM; Saucier C Methods Mol Biol; 2018; 1765():27-42. PubMed ID: 29589299 [TBL] [Abstract][Full Text] [Related]
7. HGF rescues colorectal cancer cells from EGFR inhibition via MET activation. Liska D; Chen CT; Bachleitner-Hofmann T; Christensen JG; Weiser MR Clin Cancer Res; 2011 Feb; 17(3):472-82. PubMed ID: 21098338 [TBL] [Abstract][Full Text] [Related]
8. The potential therapeutic and prognostic impacts of the c-MET/HGF signaling pathway in colorectal cancer. Parizadeh SM; Jafarzadeh-Esfehani R; Fazilat-Panah D; Hassanian SM; Shahidsales S; Khazaei M; Parizadeh SMR; Ghayour-Mobarhan M; Ferns GA; Avan A IUBMB Life; 2019 Jul; 71(7):802-811. PubMed ID: 31116909 [TBL] [Abstract][Full Text] [Related]
9. Heparan sulfate-modified CD44 promotes hepatocyte growth factor/scatter factor-induced signal transduction through the receptor tyrosine kinase c-Met. van der Voort R; Taher TE; Wielenga VJ; Spaargaren M; Prevo R; Smit L; David G; Hartmann G; Gherardi E; Pals ST J Biol Chem; 1999 Mar; 274(10):6499-506. PubMed ID: 10037743 [TBL] [Abstract][Full Text] [Related]
11. C-Met pathway promotes self-renewal and tumorigenecity of head and neck squamous cell carcinoma stem-like cell. Lim YC; Kang HJ; Moon JH Oral Oncol; 2014 Jul; 50(7):633-9. PubMed ID: 24835851 [TBL] [Abstract][Full Text] [Related]
12. Negative control of the HGF/c-MET pathway by TGF-β: a new look at the regulation of stemness in glioblastoma. Papa E; Weller M; Weiss T; Ventura E; Burghardt I; Szabó E Cell Death Dis; 2017 Dec; 8(12):3210. PubMed ID: 29238047 [TBL] [Abstract][Full Text] [Related]
13. Increased HGF Expression Induces Resistance to c-MET Tyrosine Kinase Inhibitors in Gastric Cancer. Ahn SY; Kim J; Kim MA; Choi J; Kim WH Anticancer Res; 2017 Mar; 37(3):1127-1138. PubMed ID: 28314274 [TBL] [Abstract][Full Text] [Related]
14. Transcriptional targets of hepatocyte growth factor signaling and Ki-ras oncogene activation in colorectal cancer. Seiden-Long IM; Brown KR; Shih W; Wigle DA; Radulovich N; Jurisica I; Tsao MS Oncogene; 2006 Jan; 25(1):91-102. PubMed ID: 16158056 [TBL] [Abstract][Full Text] [Related]
15. MET-mediated resistance to EGFR inhibitors: an old liaison rooted in colorectal cancer stem cells. Boccaccio C; Luraghi P; Comoglio PM Cancer Res; 2014 Jul; 74(14):3647-51. PubMed ID: 24986519 [TBL] [Abstract][Full Text] [Related]
16. MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors. Luraghi P; Reato G; Cipriano E; Sassi F; Orzan F; Bigatto V; De Bacco F; Menietti E; Han M; Rideout WM; Perera T; Bertotti A; Trusolino L; Comoglio PM; Boccaccio C Cancer Res; 2014 Mar; 74(6):1857-69. PubMed ID: 24448239 [TBL] [Abstract][Full Text] [Related]
17. Hepatocyte growth factor/MET in cancer progression and biomarker discovery. Matsumoto K; Umitsu M; De Silva DM; Roy A; Bottaro DP Cancer Sci; 2017 Mar; 108(3):296-307. PubMed ID: 28064454 [TBL] [Abstract][Full Text] [Related]
18. Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway. Wu H; Fan F; Liu Z; Shen C; Wang A; Lu Y Cancer Chemother Pharmacol; 2015 Aug; 76(2):307-15. PubMed ID: 26063323 [TBL] [Abstract][Full Text] [Related]
19. CD44-independent activation of the Met signaling pathway by HGF and InlB. Dortet L; Veiga E; Bonazzi M; Cossart P Microbes Infect; 2010 Nov; 12(12-13):919-27. PubMed ID: 20670691 [TBL] [Abstract][Full Text] [Related]
20. Targeting the MET gene for the treatment of non-small-cell lung cancer. Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]